References
- LozanoRNaghaviMForemanKGlobal and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet201238098592095212823245604
- MathersCDLoncarDProjections of global mortality and burden of disease from 2002 to 2030PLoS Med2006311e44217132052
- LangePChronic obstructive pulmonary disease and risk of infectionPneumonol Alergol Pol200977328428819591100
- LvYLvQLvQLaiTPulmonary infection control window as a switching point for sequential ventilation in the treatment of COPD patients: a meta-analysisInt J Chron Obstruct Pulmon Dis2017121255126728490869
- YangHHLaiCCWangYHSevere exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonistInt J Chron Obstruct Pulmon Dis2017122477248528860742
- ManciniGBEtminanMZhangBLevesqueLEFitzGeraldJMBrophyJMReduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary diseaseJ Am Coll Cardiol200647122554256016781387
- WangCYLaiCCYangWCThe association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients’ life quality with COPD in Taiwan (IMPACT) studyInt J Chron Obstruct Pulmon Dis2016112775278327877031
- CimenPUnluMKirakliCShould patients with COPD be vaccinated?Respir Care201560223924325316894
- KimJLeeJKHeoEYChungHSKimDKThe association of renin-angiotensin system blockades and pneumonia requiring admission in patients with COPDInt J Chron Obstruct Pulmon Dis2016112159216627672320
- PappMLiXZhuangJWangRUhalBDAngiotensin receptor subtype AT(1) mediates alveolar epithelial cell apoptosis in response to ANG IIAm J Physiol Lung Cell Mol Physiol20022824L713L71811880296
- ManciniGBKhalilNAngiotensin II type 1 receptor blocker inhibits pulmonary injuryClin Invest Med200528311812616021985
- LiuCLShauWYChangCHWuCSLaiMSPneumonia risk and use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockersJ Epidemiol201323534435023912052
- DialSNessimSJKezouhABenistyJSuissaSAntihypertensive agents acting on the renin-angiotensin system and the risk of sepsisBr J Clin Pharmacol20147851151115824803383
- SuberviolaBRodrigoEGonzalez-CastroASerranoMHerasMCastellanos-OrtegaÁAssociation between exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prior to septic shock and acute kidney injuryMed Intensiva2017411212728341094
- MortensenEMNakashimaBCornellJPopulation-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomesClin Infect Dis201255111466147322918991
- WuAGoodCDownsJRThe association of cardioprotective medications with pneumonia-related outcomesPLoS One201491e8579724489672
- HsuWTLaiCCWangYHRisk of pneumonia in patients with gastroesophageal reflux disease: a population-based cohort studyPLoS One2017128e018380828837700
- OtsukaMTakahashiHShiratoriMChibaHAbeSReduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonistThorax2004591313814694243
- CalleraGEAntunesTTCorreaJWDifferential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axisBiosci Rep2016365e0039827612496
- ClancyPKoblarSAGolledgeJAngiotensin receptor 1 blockade reduces secretion of inflammation associated cytokines from cultured human carotid atheroma and vascular cells in association with reduced extracellular signal regulated kinase expression and activationAtherosclerosis2014236110811525016365